Summary: A new substance named Lu AF60097 may help reduce side effects from tricyclic antidepressants in those with severe depression.Source: University of CopenhagenAbout one in five Danes are affected by depression at some point in their lives. The severe depressions may be treated with the so-called ‘tricyclic antidepressants’, an antidepressant drug that is more effective than the drugs used for mild and moderate depressions.But unfortunately, the tricyclic antidepressants also have a downside: significantly more and more serious side effects. So serious that many people stop taking the drug and thus receive no treatment for their depression.Now, researchers from the Faculty of Health and Medical Sciences at the University of Copenhagen, in collaboration with Lundbeck A/S and the National Institutes of Health in Baltimore, have discovered a substance that may solve that problem.‘We have discovered a substance, Lu AF60097, that works in a different way from the ones presently in use. If the new substance works, it may help the existing drugs get rid of the serious side effects’, says Professor at the Department of Neuroscience at the Faculty of Health and Medical Sciences, Claus Juul Løland.Therapeutic effect without side effectsSerotonin is a so-called neurotransmitter, a chemical substance found in the brain. In a person with severe depression, the level of serotonin is very low. Antidepressant drugs make adjustments to get a higher level of active serotonin.‘The antidepressants we use today work by going in and binding to the same site as serotonin on the serotonin transporter (SERT). The antidepressants block the return transport of serotonin and thereby also the removal of the active serotonin. But such blockage requires a relatively large dose of the antidepressant substance. And with the tricyclic antidepressants, that causes some serious side effects’, says Claus Juul Løland.The side effects can be anything from life-threatening heart problems to severely dry mouth, visual disorders, development of mania, weight problems and digestive challenges.The substance discovered by the researchers binds to another site on SERT: the ‘allosteric site’. When a substance binds to the allosteric site rather than the same site as serotonin, it is possible to regulate the function of the serotonin transporter instead of completely blocking it.Serotonin is a so-called neurotransmitter, a chemical substance found in the brain. In a person with severe depression, the level of serotonin is very low. Antidepressant drugs make adjustments to get a higher level of active serotonin.The image is in the public domain.‘In this case, we have shown that when we bind this substance to the allosteric site while giving the tricyclic antidepressant, we can amplify the binding of the antidepressant substance. Therefore, we can use a much smaller concentration of the antidepressant substance. It might cause fewer side effects, but have the same therapeutic effect’, says Claus Juul Løland.From concept to drugThe researchers have, over a long period of time and in several rounds, screened a number of substances from Lundbeck’s drug library to find a substance that had a sufficiently strong link to the allosteric site to make it possible to study the pharmacological effect. With Lu AF60097, they finally succeeded.But there is still a long way to go before the substance can be used as an actual drug. The researchers have shown that a substance that binds to the allosteric site can have this pronounced, pharmacological effect in cells and in rats. From here, it is up to the pharmaceutical companies to develop substances that may have the same effect in humans.‘We have taken the first step. But perhaps also the biggest. We have shown that the concept works. If it also works in practice, hopefully in the future it can be used to treat people with severe depression’.See alsoFeaturedGeneticsNeurosciencePsychology·December 12, 2019Could some people with schizophrenia in poorer nations simply have a vitamin deficiency?[divider]About this neuroscience research article[/divider]Source: University of Copenhagen Media Contacts: Claus Juul Løland – University of Copenhagen Image Source: The image is in the public domain.Original Research: Open access “The mechanism of a high-affinity allosteric inhibitor of the serotonin transporter”. Per Plenge, Ara M. Abramyan, Gunnar Sørensen, Arne Mørk, Pia Weikop, Ulrik Gether, Benny Bang-Andersen, Lei Shi & Claus J. Loland. Nature Communications doi:10.1038/s41467-020-15292-y.AbstractThe mechanism of a high-affinity allosteric inhibitor of the serotonin transporterThe serotonin transporter (SERT) terminates serotonin signaling by rapid presynaptic reuptake. SERT activity is modulated by antidepressants, e.g., S-citalopram and imipramine, to alleviate symptoms of depression and anxiety. SERT crystal structures reveal two S-citalopram binding pockets in the central binding (S1) site and the extracellular vestibule (S2 site). In this study, our combined in vitro and in silico analysis indicates that the bound S-citalopram or imipramine in S1 is allosterically coupled to the ligand binding to S2 through altering protein conformations. Remarkably, SERT inhibitor Lu AF60097, the first high-affinity S2-ligand reported and characterized here, allosterically couples the ligand binding to S1 through a similar mechanism. The SERT inhibition by Lu AF60097 is demonstrated by the potentiated imipramine binding and increased hippocampal serotonin level in rats. Together, we reveal a S1-S2 coupling mechanism that will facilitate rational design of high-affinity SERT allosteric inhibitors.[divider]Feel Free To Share This Neuroscience News.[/divider]Join our Newsletter I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.comWe hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.